ORPHAN DRUGS FEATURETTE
November 1st, 2003
BY ALAN OSBORNTHREE years after it was launched by the London-based European Agency for the Evaluation of Medicinal Products (EMEA), the new procedure for the designation of orphan drugs and for assisting in their development is widely judged a success though there remain serious questions over actually getting the authorised drugs to patients.Under the system, administered by the Agency's Committee for Orphan Medicinal Products (COMP), there is a 100 per cent waiver of protocol assistance fees for products designated as orphan drugs and a 50 per cent waiver on ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.